Executive Interview: BioNeutral Group CEO Mark Lowenthal
Mar 5, 2014 8:57 AM | about stocks: BONU
My executive Q & A series has been going very well. I've interviewed some great CEO's in the Small and microcap arenas. Earlier this week I was fortunate enough to have a chance to site down with Mark Lowenthal, CEO of Bioneutral Group Inc. This company was one that I had reported on a few months ago and have been following since mid November of 2013. It seems like the company has just started to build in the 2014 year and after having had the chance to discuss BONU with the company's CEO, I feel that this will be something that I'll continue to follow throughout the year:
Executive Interview with BioNeutral Group CEO Mark Lowenthal
1. In a few words, can you explain what the company does or is planning to do?
Over the last seven years our Company has developed, tested and is now in the process of commercially introducing a series of state of the art and highly competitive sterilization and bioneutralizer products (products that kill micro-organisms on surfaces and eliminate odors in the air at the cellular level). The products have wide applications in various health and life science segments (acute and long-term care, veterinary care, first response, laboratory research, pharma manufacturing), and in industrial segments (janitorial, sanitation, mold remediation, hospitality), both here at home and abroad. They also have substantial applications across various government and consumer markets as well.
With our testing substantially performed as of late 2012, we began 2013 by first accessing the various marketplaces, then developed a focused sales plan, and finally in the later part of the year began to engage independent sales agents, i.e. independent sales groups and distributors.
Overall we've found the markets extremely receptive, and beginning in 2014 we now believe we are finally beginning to be in a position to leverage our technology. To date we have been severely hampered by being undercapitalized and lacking the resources with which to do this.
2. What Direction do you see your industry headed toward?
There is a continually growing movement on a worldwide basis towards higher standards of sterility and high-level disinfection across a wide variety of market segments which we plan to engage in. In this respect, as a high quality and highly efficacious supplier we have high expectations.
3. What are the key risks the company faces right now?
We feel our chief constraint is our access is to capital. Like most small companies, locating cost effective sources of capital can be (and in the past has proven to be) somewhat tricky. However I will say we are making progress in that area and as things stand currently, I feel our prospects have improved.
4. What projects are you currently looking to begin and/or complete?
We are currently in the process of negotiating a supply agreement and a private label transaction with two major market distributors for coverage both here at home and abroad. In addition, we are also in discussions with a major distributor for a key market segment, and we are close to an agreement to begin consumer testing our Ogiene products overseas.
5. What are the current challenges you're facing that could prevent or slow progress from this/these project(s)?
As mentioned above, access to capital.
6. If all goes as planned, how much revenue does the company anticipate generating from this/these project(s)?
We are in the early stages of commercialization and in the process of collecting new market data all the time, and that being said, over the next five years or so my goal is to have the Company generate sales in the $150,000,000 range.
7. How are you currently marketing your product/brand?
By engaging with firms for supply agreements, distribution agreements, private label transactions and independent sales groups.
8. Where do you think the most significant growth will occur for the company over the next 3-6months?
Four key market segments, laboratory research, pharmaceutical and compound manufacturing, janitorial/sanitation and mold remediation
9. You're the CEO of a small cap company. What is the major discerning factor that sets the company apart from the rest and gives you a competitive advantage?
Our proprietary combinational chemistry that makes up our technology; which is highly effective, highly competitive and cost effective.
10. What are you doing to capitalize on the company's strengths and minimize the company's weakness?
We are actively engaged in micro financial markets and are accessing capital there to finance much of our operations and plan to continue to do so.
11. Are you self-funding your projects or do you work with funding sources as a means for operational cash flow?
Our goal is to become financially self-sufficient through our operations as soon as possible. At the current time we are working with a few lending sources.
12. Is there anything that shareholders should know about you personally?
I am a highly trained and fairly successful professional manager. Shareholders can find my bio on line. I am heavily invested in the company, and as such am committed to its success.
It was a pleasure speaking with Mr. Lowenthal and I would like to thank him for his time. Having had the opportunity to discuss several specific topics sheds more light on the company's direction for the new year and even beyond. Until next time,
http://bioneutral.com/Home/Page/products-ogiene http://spectrasan.com/rokdownloads/sales_materials/ogiene-sell-sheet.pdf The Importance about Spectrasan: Ygiene and Ogiene from BONU is listed as the top products on the Spectrasan website: Ygiene and Ogiene from BONU is listed as the top products on the Spectrasan website:
Read below from some older news to possibly link an affiliation:
BioTech Medical, LLC, a privately held company announced Monday that it is prepared with its new product SpectraSan 24, a new advanced surface disinfectant to immediately respond to the current Influenza A (H1N1) epidemic. BioTech Medical, LLC is a distributor for PURE Bioscience (Nasdaq: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial. …
PURE trades on the NASDAQ at $1.10+ per share:
These relationships are definitely something that we should keep our eye on for sure. http://bioneutral.com/Home/Page/bioneutral-group
Dr. Andy Kielbania, was with was Rohm and Haas which was a very huge multi-billion dollar company. In my opinion, him being here with BONU is a huge hint that he is not here because of something that could be considered small change. See below:
Quote: Dow Chemical
Rohm and Haas | Company Information from ICIS In April 2009, Dow Chemical completed its $78/share takeover of Rohm and Haas. Dow Chemical will integrate its acquired Rohm and Haas business into the newly formed ‘Advanced Materials Division’ and will be headed by Pierre Brondeau.
bought out Rohm and Haas
for $78.00 per share.
When you click on the old Rohm and Haas
website, it takes you to Dow Chemicals
website: http://www.rohmhaas.com For inquiring minds, Dow Chemicals trade on the NYSE at $40.00+ per shareunder the ticker pf DOW: http://www.dow.com/ More proof that Dr. Andy Kielbania, PhD, CEO, Chief Scientific Officer and Director for BONU was an instrumental part of Rohm and Haas which was bought out by Dow Chemical:
At Rohm and Haas we thank Dr. Edward Firouztale, Dr. Peter Cartier, and Dr. Andy Kielbania for scholarly discussions and assistance with the research.
Dr. Andy Kielbania, PhD
The Chief Scientist with over 35 years experience in the specialty chemical field, including coatings, adhesives, personal care, biotechnology and pharmaceuticals. He has previously held positions at Rohm and Haas (do people realize how big these Companies are?) where he assumed senior level positions in research and development. In 1993, Dr. Kielbania joined National Starch and Chemical Company (part of ICI) as research and development Director. Dr. Kielbania is the inventor on 21 patents and has published many technical articles. He is the winner of awards in new technology development to improve new business opportunities and also research and development improvements. He received his PhD in organic chemistry from the University of California at Berkeley (good grief it does not get any better than that other than Harvard and MIT!) and has post doctoral experience at Stanford University.
Disinfectant that quickly wipes out swine flu, anthrax spores, is being tested at NJIT
Hospital Grade Antimicrobial passed the AOAC Use Dilution test by totally eradicating all five million colony forming units of MRSA in less than one minute (fifty-nine seconds) at room temperature. Hospital induced Staph Infection & H1N1 Flu Virus
The required EPA testing procedures occurred at ATS Labs.
BioNeutral’s Ygiene™ Kills Dangerous MRSA in Seconds. Hospital Acquired Infections (HAI’s), The big one ( staph Infection)
BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based life science company, reports that its Ygiene™ Hospital Grade Antimicrobial passed the AOAC Use Dilution test by totally eradicating all five million colony forming units of MRSA in less than one minute (fifty-nine seconds) at room temperature. The required EPA testing procedures occurred at ATS Labs.
MRSA, or Methicillin-resistant Staphylococcus aureus, is a very serious health threatening microorganisms present in many health care facilities and community environments. MRSA is one of the more serious antibiotic resistant heath threatening microorganisms that contributes to Hospital Acquired Infections (HAI’s). In the U.S. alone, over two million people annually are afflicted with Hospital Acquired Infections with approximately one hundred thousand people dying. Worldwide Hospital Acquired Infections are on the rise and will lead to hundreds of thousands needless deaths annually. MRSA is also becoming a serious issue associated with Community Acquired Infections such as school and campus settings. With its power to rapidly and totally eliminate MRSA in less than one minute, BioNeutral’s Ygiene™ Hospital Grade Antimicrobial will be a significant part of the future solution for controlling Hospital Acquired Infections and Community Acquired Infections.
BioNeutral’s Consumer Grade Ygiene™ Delivers a 100% Total Kill on Contact of Swine Flu (H1N1) Virus – For the Home
BioNeutral Announces 100% Total Kill of Swine Flu (H1N1) on Virtual Contact of This Pandemic Causing Virus in an Independent ...
Swine Flu Campaign Waits on Vaccine
Only Third of Supply Is Expected for First Round of Vast Effort
By Rob Stein
Washington Post Staff Writer
Sunday, August 23, 2009
New York Times
Monday, August 24, 2009
BioNeutral Group Hosts Discussions with Four of the World’s Largest Health Care Companies
All Interested in Ygiene™ Sporicidal Antimicrobial Performance on Skin and Surfaces
Monday, August 24, 2009
211 Warren Street
Newark, NJ 07103
3 Month Daily View